Strengthening our presence in the Chinese market for Rapid Transfer Systems

ABC Transfer is proud to announce a new strategic partnership with Shanghai HanKing Instrument & Equipment Co., Ltd, reinforcing our international expansion and strengthening our presence in the Chinese market.

This collaboration marks an important milestone in ABC Transfer’s global development strategy and supports the growing demand for rapid transfer systems in China for pharmaceutical and biotech applications. Through this partnership, we will provide enhanced local support, distribution, and technical expertise to customers across the country.

 

About Shanghai HanKing Instrument & Equipment Co., Ltd

Founded in 2009 and headquartered in Shanghai, Shanghai HanKing Instrument & Equipment Co., Ltd is a well-established distributor specializing in high-quality instruments, equipment, and technical services for laboratories and industrial applications.

With a strong commercial network and extensive market knowledge, Shanghai HanKing serves industries such as biopharmaceuticals, food production, chemical manufacturing, and research institutions throughout China.

Their expertise in distribution, logistics, and customer support makes them a trusted partner for international companies seeking reliable access to the Chinese market, including companies developing aseptic processing and rapid transfer system solutions in China.

Contact us

H2 A Strategic alliance to better serve our customers

Through this partnership, ABC Transfer aims to:
•    Strengthen the distribution of our RTP solutions in China
•    Provide responsive local technical and commercial support
•    Enhance customer proximity and service quality

By combining ABC Transfer’s expertise in sterile transfer technology with Shanghai HanKing’s strong local presence, we ensure that Chinese customers benefit from high-performance solutions backed by reliable on-the-ground support.

 

Supporting growth in a dynamic market

China represents a key strategic market with significant industrial growth and increasing demand for high-quality technical solutions.
By partnering with Shanghai HanKing Instrument, ABC Transfer continues to expand its international footprint while maintaining its commitment to:
•    Innovation
•    Quality manufacturing
•    Technical excellence
•    Long-term customer relationships

The pharmaceutical and biotech sectors increasingly require advanced aseptic transfer and rapid transfer systems to meet regulatory standards and ensure contamination control.

 

About ABC Transfer

At ABC Transfer, we design, manufacture, and distribute ultraclean sterile transfer solutions specifically tailored for the pharmaceutical and biotech industries. Our portfolio includes high-performance Rapid Transfer Systems (RTS), such as Alpha ports, Beta containers, single-use bags, and the ABC Transfer ULTRA system, developed in close collaboration with pharmaceutical manufacturers and isolator partners to meet stringent GMP and sterility requirements.

These solutions support advanced aseptic processes and are widely used in environments requiring high-performance rapid transfer systems, including applications in cell therapy, nanopowders, and advanced biological manufacturing.

 

Contact ABC Transfer

 

“ABC Transfer & Sychem: A Strategic Partnership to Advance Sterile Transfer Solutions in the UK & Northern Ireland”

We are proud to announce our new strategic partnership with Sychem, a leading UK provider of sterilisation, hygiene, and life-science solutions. With more than 40 years of expertise in infection control and decontamination, Sychem is a trusted partner to pharmaceutical manufacturers, laboratories, and controlled-environment facilities across the UK and Northern Ireland, supplying advanced equipment and services backed by strong technical support and UKAS-accredited validation services.

About ABC Transfer’s Sterile Transfer Expertise

At ABC Transfer, we design, manufacture, and distribute ultraclean sterile transfer solutions specifically tailored for the pharmaceutical and biotech industries. Our portfolio includes high-performance Rapid Transfer Systems (RTS), such as Alpha ports, Beta containers, single-use bags, and the ABC Transfer ULTRA system, developed in close collaboration with pharmaceutical manufacturers and isolator partners to meet stringent GMP and sterility requirements.
These solutions address key industry challenges—including patient safety, regulatory compliance, ergonomic handling, and ultra-clean conditions required for next-generation therapies like cell therapy, nanopowders, and advanced biologicals—enhancing both safety and operational efficiency in aseptic environments.

 

Contact ABC Transfer

Why This Partnership Matters

The collaboration between ABC Transfer and Sychem brings together global innovation in sterile transfer technology and local UK market expertise in hygiene and controlled-environment solutions:
•    Enhanced Market Reach: Sychem will support the introduction and distribution of ABC Transfer’s RTS products throughout the UK & Northern Ireland, leveraging its established relationships with pharmaceutical manufacturers and controlled-environment facilities.
•    Local Expertise & Service: Beyond sales, Sychem provides expert consultancy, installation, UKAS-accredited validation, servicing, and maintenance—ensuring customers receive tailored support throughout the lifecycle of the equipment.
•    Complementary Technology: Sychem’s portfolio already includes advanced sterilisation, washer-disinfectors, isolators, and VHP decontamination solutions tailored to pharma and biopharma environments; the integration of ABC Transfer’s aseptic transfer systems strengthens that offering, providing a more complete solution for sterile production environments.

Driving Aseptic Manufacturing Forward

As pharmaceutical manufacturing evolves—driven by increasingly complex biologics, stricter regulatory expectations, and a need for higher throughput and sterility assurance—aseptic process equipment must be both innovative and robust. ABC Transfer’s solutions are designed with these evolving needs in mind, combining:
•    Superior sterility assurance and ultra-clean transfer environments
•    Ergonomics and operator safety
•    Compatibility with isolators, RABS, and automated systems
•    Sustainable design principles with reduced material use and recyclability in mind
Sychem’s deep experience in controlled environment services and validation further enhances these capabilities for UK-based customers, facilitating streamlined adoption and compliance across facilities.

What’s Next

Over the coming months, we will be working closely with Sychem to support product demonstrations, informational sessions, and deep-dive technical engagements with pharmaceutical manufacturers. If you are seeking to integrate next-generation sterile transfer solutions into your facility, contact our teams at ABC Transfer or Sychem to explore the benefits and technical fit for your processes.
Together, ABC Transfer and Sychem are committed to delivering cutting-edge, compliant, and high-performance sterile transfer solutions—helping the life sciences industry meet its most demanding challenges with confidence.”

 

Impact of the EU GMP Annex 1 (2022) on Rapid Transfer Ports (RTPs)

1. Introduction

The 2022 revision of Annex 1 of the EU GMP Guidelines has profoundly reshaped sterile manufacturing expectations across the pharmaceutical industry. Beyond reinforcing contamination control principles, it introduces a risk-based, holistic framework that integrates facility design, equipment qualification, and procedural control into a unified Contamination Control Strategy (CCS). Among the components most directly affected are Rapid Transfer Ports (RTPs) and their associated beta systems, which form the critical mechanical interface between aseptic cores and external environments. As these interfaces are repeatedly actuated, sterilized, and validated throughout the product lifecycle, they play a defining role in the overall sterility assurance level (SAL) of a process. This article explores how the Impact of the EU GMP Annex 1 (2022) on Rapid Transfer Ports influences their design, validation, and lifecycle management, and how forward-looking suppliers such as ABC Transfer have integrated these regulatory expectations into their product design philosophy.

2. From Containment to Contamination Control Strategy (CCS)

Annex 1’s most significant conceptual shift is the move from containment-focused design to a comprehensive contamination control strategy. The text specifies that every barrier, interface, and component must be assessed for its contribution to sterility assurance. For RTPs, this means demonstrating that the transfer interface actively supports contamination prevention, not merely by procedural control but by inherent mechanical and material performance. The Impact of the EU GMP Annex 1 (2022) on Rapid Transfer Ports is therefore evident in the requirement to incorporate RTP-specific risk assessments and failure mode analyses (FMEA) into the global CCS documentation, and to document how the RTP reduces manual interventions, wear, and particle generation consistent with Annex 1 §§2.3, 4.1, and 8.4. Consequently, RTP manufacturers must now deliver not only robust mechanical designs but data-backed validation evidence: cleanability, integrity, and compatibility data that end users can integrate into their CCS files.

 

 

Discover secure rapid transfer ports from ABC Transfer®

 

3. Design Evolution Driven by Annex 1 Requirements

Annex 1 does not prescribe specific hardware designs but sets performance expectations that directly influence RTP architecture. Leak-Tightness and Integrity Testing (§§4.4, 8.86) emphasize that closed systems must maintain validated integrity before and after aseptic processing. The Impact of the EU GMP Annex 1 (2022) on Rapid Transfer Ports is reflected in the adoption of leak tests with thresholds below 10⁻⁴ Pa·m³/s (as defined in ISO 10648-2:1994, Class 2 or better) (ISO 10648-2 : 1994 / EN ISO 10648-2), seal integrity over 1,000–5,000 cycles, and requalification after sterilization or gamma irradiation. These requirements have pushed suppliers to adopt redundant O-rings, self-centering bayonet couplings, and surface finishes (Ra ≤ 0.8 µm) minimizing microbial retention and mechanical wear. Particle Control and Friction Reduction (§8.8) stresses minimizing particulate contamination during transfer. Modern designs feature low-friction PEEK or PTFE components, dry lubrication coatings, and optimized ‘ring of concern’ geometries to reduce abrasion during docking. Material Compatibility and Single-Use Integration (§8.47) encourages the use of single-use beta components. High-density polyethylene (HDPE) and ethylene-vinyl acetate (EVA) beta bags, validated for 25–50 kGay gamma cycles, now offer safer, traceable, and contamination-resistant transfer options. Integration of RFID traceability and unique beta port identifiers enables digital linkage between RTPs, sterilization batches, and production records;  key for data integrity compliance under ICH Q9(R1) and Annex 1 §2.7.

4. Validation and Documentation Expectations

The Impact of the EU GMP Annex 1 (2022) on Rapid Transfer Ports also extends to validation and documentation practices. The revised Annex 1 (§§2.5, 8.87) demands documented, scientific justification of all critical process elements. For RTP systems, this includes Design Qualification (DQ) confirming design alignment with CCS-derived user requirements; Installation & Operational Qualification (IQ/OQ) testing of assembly integrity, pressure hold performance, torque verification, and cleanability; Performance Qualification (PQ) under operational conditions, including aseptic transfers with microbiological challenge testing; and requalification based on defined frequency or event-driven triggers. Suppliers are expected to provide comprehensive Validation Master Files containing leak rate test reports, particle emission results, extractables/leachables profiles, and irradiation validation summaries.

5. Integration with Isolators, RABS, and CCS Monitoring

In aseptic manufacturing, RTPs form a crucial interface between isolators or RABS and the external environment. Annex 1 (§8.46) explicitly requires the use of validated, closed transfer systems when introducing sterile components into aseptic zones. The Impact of the EU GMP Annex 1 (2022) on Rapid Transfer Ports has made RTP seals part of automatic pre-use leak tests (PULT) in isolator-based production, RTP seals are now often included in automatic pre-use leak tests (PULT) ensuring barrier integrity before each batch. In RABS, risk assessments must demonstrate that the RTP maintains Grade A–B segregation even during operator proximity. Digital monitoring systems now integrate pressure sensors, actuation counters, and RFID event logs, providing traceable proof of performance within the CCS framework. The modern RTP is therefore no longer a passive device but an instrumented component of a monitored contamination control ecosystem.

 

 

Contact us to discover our solutions

 

6. Supplier Qualification and Lifecycle Management

Annex 1 (§§ 2.5 and 8.13) requires that critical equipment suppliers demonstrate quality management systems equivalent to pharmaceutical expectations and a solid understanding of GMP requirements. The Impact of the EU GMP Annex 1 (2022) on Rapid Transfer Ports has extended to supplier management practices, meaning RTP manufacturers must produce under ISO 9001 or ISO 13485 with documented traceability, maintain change control procedures, deviation and CAPA management, and offer requalification support and periodic audits. End users now integrate RTP suppliers into their qualification programs — reviewing design, process capability, batch traceability, and continuous improvement records.

7. Future Directions: Data-Driven Sterile Transfer

Annex 1’s emphasis on data integrity and continuous improvement has accelerated the transition toward smart RTP systems. Next-generation solutions under development include embedded sensors for continuous pressure verification, predictive maintenance analytics using actuation data, and secure digital traceability, potentially leveraging blockchain or equivalent technologies of beta bags linking sterilization batch, irradiation dose, and usage events. This evolution supports the digital GMP ecosystem, where every aseptic transfer event generates structured data supporting real-time CCS oversight. Effective lifecycle management also encompasses deviation handling and CAPA processes, ensuring that any non-conformities identified through RTP monitoring feed back into the site’s continuous improvement system.

8. Conclusion of Impact of the EU GMP Annex 1 (2022) on Rapid Transfer Ports

The revised EU GMP Annex 1 has redefined expectations for aseptic process equipment. For Rapid Transfer Ports, compliance now demands more than mechanical precision — it requires integrated design, data integrity, and full lifecycle traceability. Manufacturers aligning their RTP systems with Annex 1 principles gain not only regulatory assurance but operational efficiency, reduced downtime, and audit readiness. In short, Annex 1 has turned the RTP from a mechanical connector into a strategic control point of aseptic manufacturing.

9. ABC Transfer’s Commitment to Annex 1 Compliance and Future Innovations

Since 2019, ABC Transfer has anticipated the regulatory evolution brought by Annex 1 and progressively aligned the design of its Rapid Transfer Ports with the highest contamination control requirements. The company’s development roadmap is driven by the philosophy of ‘Contamination Control by Design’, combining mechanical innovation, advanced materials, and operational simplicity to ensure robustness, reproducibility, and compliance across all aseptic environments. Key initiatives include redesigned alpha ports, including the Gloveless Alpha Port and the ULTRA solution, which eliminate the need for manual intervention during transfer operations, thereby reducing contamination risk and enhancing ergonomics. These technologies exemplify ABC Transfer’s commitment to minimizing human factors while maintaining full mechanical compatibility with existing isolator systems. Enhanced beta bag validation programs encompass extended gamma aging studies, extractables and leachables analyses, and mechanical fatigue testing to guarantee long-term reliability under Annex 1’s stricter integrity requirements. Introduction of PEEK-based docking mechanisms delivers superior wear resistance, dimensional stability, and ease of cleaning compared with traditional stainless-steel or polymer assemblies. Beyond product design, ABC Transfer collaborates closely with isolator manufacturers, regulatory experts, and pharmaceutical partners to define best practices for sterile transfer validation and lifecycle documentation. Its engineering teams actively contribute to international working groups to ensure that the company’s solutions remain fully aligned with both Annex 1 and future revisions of global aseptic manufacturing standards. Looking ahead, ABC Transfer will continue to develop next-generation RTP systems offering enhanced robustness, simplified maintenance, and seamless integration into digital CCS environments; ensuring sustained compliance and operational excellence for its customers worldwide.

We are delighted to announce that our two directors, Thierry Girard (President & Founder) and Jean-Luc Schneider (Managind Director & Founder), will be attending the next A3P International Congress in Biarritz, France which will take place from October 7 to 9, 2025.

An unmissable event for operators in the pharmaceutical and biotechnlogy industry, the A3P International Congress is a unique venue for meetings and discussions on the themes of sterility, quality, and innovation.

The presence of our executives at this event illustrates ABC Transfer’s committment to remaining at the forefront of sterile transfer solutions and to engaging in direct dialogue with decision-makers in the sector.

Come and meet our team on October 7, 8, and 9, 2025, at Espace Océan – Stand O14: we look forward to sharing our expertise with you and discussing your projects to meet the challenges of your business.

See you in Biarritz!

 

 

Book a demo/meeting

 

Qualification of the ABC Transfer® Alpha-Beta Connection for Sterile Process Applications

1. Abstract

This report presents the qualifications of the ABC Transfer® Alpha-Beta Connection . The goal was to evaluate the system’s performance in maintaining sterility during material transfers. Multiple tests assessed the effects of cleaning and contamination under simulated production conditions inside a SKAN isolator. No contamination was observed inside the isolator or the Beta container, even when seals were not cleaned, demonstrating the system’s exceptional containment capabilities. These results validate the ABC Transfer® system as a very safe sterile process and aseptic transfer solution for GMP pharmaceutical operations.

2. Introduction

Transfer systems are key to preserving sterile conditions in aseptic pharmaceutical environments. ABC Transfer has developed an Alpha-Beta system that aims to optimize containment, user ergonomics, and compliance with GMP and Annex 1 standards. This report summarizes qualification results from a series of experimental tests evaluating microbial containment and decontamination across standard and challenged conditions. Emphasis is placed on real-world handling, efficacy of cleaning procedures, and the system’s capacity to protect critical sterile zones.

3. Materials and Methods

3.1 Sterile Process Equipment Used for Alpha-Beta Connection

Tests were conducted in a SKAN PSI/SARA isolator in Grade A conditions with +50 Pa overpressure. The Isolator was installed in a non-controlled environment. The tested equipment included a 270 mm Alpha port and two 270 mm Beta stainless steel containers. No filters were used on the containers, and doors remained sealed to simulate conditions of a controlled sterile process. Environmental conditions (temperature, humidity, pressure) were monitored using calibrated devices.

3.2 Microbiological Analysis

TSA agar and Bacillus stearothermophilus BIs were used. Samples were incubated at 30–35°C for 3–5 days. Surface and personnel monitoring was conducted using contact and settle plates. All microbiological assessments complied with USP <61> and EP <2.6.12>.

Contact us

4. Results of the Alpha-Beta System in Sterile Process Conditions

4.1 Test 1: Environmental Control Baseline

The objective of this test was to establish the microbiological baseline of the testing environment. To do this, settle plates and contact plates were employed to detect ambient contamination. Plates were exposed for four hours on the Alpha port and Beta container doors. Additional contact plates were applied to the protective clothing of the operators working within the isolator setup. The results indicated measurable CFUs on settle plates located on both the Alpha and Beta doors. Furthermore, moderate contamination levels were found on the operator garments, which was consistent with expectations for a controlled Grade C cleanroom environment. These results confirmed that the microbiological background was stable and representative, making it suitable for the simulation testing that followed.

4.2 Test 2: VHP Decontamination

This test was designed to validate the effectiveness of vaporized hydrogen peroxide (VHP) in eliminating microbial bioburden on the Alpha and Beta port surfaces. Biological indicators (BIs) containing Bacillus stearothermophilus spores were strategically placed on these surfaces prior to the application of a full VHP sterilization cycle. Post-exposure analysis showed that all BIs were completely inactivated, indicating the high efficacy of VHP in achieving thorough decontamination—a cornerstone of any sterile process system.. These results confirm the reliability of VHP treatment for decontaminating the Alpha-Beta interface in routine sterile operations.

4.3 Test 3: Sterility Without Cleaning

The purpose of this test was to assess whether sterility could be maintained during multiple transfer operations without any intermediate cleaning of the Alpha and Beta seals. Five consecutive transfers were performed without the application of any disinfectant. While the first two cycles yielded no contamination, one CFU was detected on the seals starting from the third cycle. Importantly, no CFUs were detected inside the Beta container or within the isolator at any stage, demonstrating that the system effectively prevents contamination of critical sterile areas even under suboptimal cleaning conditions.

Contact us

4.4 Test 4: IPA Disinfection Efficiency

This test evaluated the effectiveness of wiping the Alpha and Beta seals with sterile wipes soaked in 70% isopropyl alcohol (IPA) between each of five transfer cycles. Microbiological sampling confirmed that this practice successfully prevented the development of any microbial contamination, both on the seals and within the container and isolator. These findings support the integration of IPA wiping as a practical and effective disinfection method during routine aseptic transfers.

4.5 Test 5: Deliberate Seal Contamination (100 CFU)

To simulate a worst-case scenario, 100 colony forming units (CFUs) of Bacillus stearothermophilus were deliberately applied to the Alpha and Beta seals prior to five successive transfers. No cleaning was performed between transfers. While external contamination was observed on the ring of concern and peripheral Beta seal surfaces, no CFUs were detected inside the Beta container or inside the isolator. This outcome demonstrates that the ABC Alpha-Beta system contains microbial contamination externally and maintains a sterile process even in highly challenging conditions.

4.6 Test 6: Hydrogen Peroxide Surface Bioburden Reduction

This test was conducted to confirm the bioburden reduction capacity of a 6% hydrogen peroxide (H₂O₂) solution when applied manually as a surface disinfectant. Following deliberate contamination, all surfaces were wiped using sterile wipes soaked in the H₂O₂ solution. Subsequent microbiological sampling demonstrated a significant reduction in CFUs, with residual contamination consistently below 10 CFU per surface. This confirms the effectiveness of hydrogen peroxide in high-level disinfection of transfer interfaces.

4.7 Test 7: Container Sterility Over Time

This test assessed the ability of a Beta container to maintain sterility when stored outside the isolator for an extended period. The sealed container was disconnected from the isolator and left under controlled conditions for 96 hours. Upon re-connection, microbiological samples were taken from internal surfaces. No microbial growth was detected, demonstrating that the system preserves internal sterility for at least four days.

5. Discussion: Performance and Reliability in Sterile Process Qualification

The comprehensive testing program confirmed the robustness of the ABC Transfer Alpha-Beta system under a wide range of conditions. Tests 1 and 2 established a reliable environmental baseline and validated the effectiveness of VHP decontamination. Tests 3 through 5 demonstrated that the internal sterile volume of the Beta container and the isolator remained sterile even when the seals were not cleaned or deliberately contaminated. The results from Test 4 supported the use of 70% IPA as a practical and effective cleaning solution. Test 6 showed that hydrogen peroxide provided high-level bioburden reduction, while Test 7 confirmed that the Beta container retained sterility for up to four days of storage outside the isolator. Importantly, in no test scenario was contamination detected inside the container or the isolator, highlighting the superior containment performance of the system.

Contact us

6. Conclusion

The qualification study demonstrated that the ABC Transfer Alpha-Beta connection is a reliable and safe solution for aseptic material transfer in pharmaceutical environments. Across all test scenarios, no microbial contamination was found inside the Beta container or the isolator, even under adverse conditions such as multiple uncleaned transfers or deliberate inoculation. The system effectively contains potential contaminants at the seal interface and maintains sterile boundaries. Its compatibility with IPA and hydrogen peroxide disinfection protocols, along with the demonstrated integrity of the Beta container during storage, confirms the ABC system’s suitability for GMP-compliant sterile process manufacturing operations. It is recommended as a best-in-class aseptic transfer solution.

 

Managing the “Ring of Concern” in Rapid Transfer Systems; Risks, Realities, and Mitigations”

Introduction

In sterile pharmaceutical manufacturing, ensuring aseptic conditions during material and component transfers is fundamental. Rapid Transfer Ports (RTPs) provide a reliable solution for transporting products between isolated environments, such as isolators or Restricted Access Barrier Systems (RABS), and cleanrooms. Originally designed in the 1960s by the French Atomic Energy Commission for use in the nuclear industry, Rapid Transfer Ports have since been adapted for pharmaceutical applications, notably for handling high-potency active pharmaceutical ingredients (HPAPIs) and sterile items requiring stringent contamination control.

 

Among the structural features of Rapid Transfer Port systems, a particular focus has emerged around a small interface zone termed the “Ring of Concern”. This region, located at the junctioni between the alpha and beta ports, represents a potential microbial contamination route during transfer operations. WIth evolving regulatory expectations, such as those found in the 2022 revision of EU GMP Annex 1, there is increased scrutiny on any element that may compromise sterility assurance. This article evaluates the scientific and operational basis for managing the Ring of Concern in Rapid Transfer Ports through a combination of theoretical modeling, empirical evidence, and engineering controls.

Methods

The assessment of the Ring of Concern involved four primary methodologies: theoretical surface contamination modeling, empirical microbial monitoring from pharmaceutical production sites, evaluation of chemical disinfection effectiveness, and review of mechanical control strategies integrated within Rapid Tranfer Port systems.

The Ring of Concern itself is an annular strip approximately 0.2 mm wide with a diameter of 190 mm, resulting in a total surface area of around 119 mm², on ABC Transfer® Rapid Transfer Ports . For context, the associated alpha and beta seals measure approximately 7,000 mm² and 5,300 mm² respectively. Microbial contamination estimates were derived using typical cleanroom microbial densities—Grade C (25 cfu/55 mm plate) and Grade D (50 cfu/55 mm plate)—to simulate worst-case transfer conditions.

Surface microbial testing data was gathered from two commercial pharmaceutical manufacturing facilities. Both sites employed swabbing of Rapid Transfer Port seals and contact media plates incubated at 30–35°C. Disinfectant efficacy studies focused on common industry agents such as 70% isopropyl alcohol (IPA), Actril®, SPOR-KLENZ®, and VESTA-SYDE®. Engineering mitigations included flexible sleeves, retractable rigid channels (plastic and stainless steel), and motorized guides integrated into ported bags.

Results

Theoretical calculations based on microbial loads in Grade D environments suggest the following contamination potentials:
– Alpha seal: (50 × 7,000) / [(π × (55/2)²)] ≈ 147 cfu
– Beta seal: (50 × 5,300) / same denominator ≈ 112 cfu
– Ring of Concern: (50 × 119) / same denominator ≈ 2.5 cfu

In Grade C environments, these figures drop approximately by half, confirming the relationship between ambient cleanliness and surface bioburden.

Real-world contamination monitoring from Site 1 (533 tests) yielded only one positive result, attributed to operator error. Site 2 (86 tests) recorded no microbial growth. These data strongly suggest that with routine disinfection and procedural discipline, contamination of the Ring of Concern is exceedingly rare.

Disinfection results demonstrated the following:
– IPA 70% achieved >3-log microbial reduction with 1-minute contact time against common environmental isolates.
– Actril® achieved >4-log reduction on *Aspergillus niger* and 3-log on *Bacillus subtilis* after 5 minutes, though noted for corrosiveness.
– SPOR-KLENZ® demonstrated complete inhibition of *Clostridium sporogenes* growth after 5.5 hours per AOAC method 966.04.
– VESTA-SYDE® offered broad bactericidal, fungicidal, and virucidal efficacy per EPA testing standards.

Engineering controls further enhanced safety:
– Flexible sleeves: Integrated into ported bags to direct components away from the Rapid Transfer Port seals.
– Plastic retractable channels: Prevent contact during transfers and retract post-operation.
– Stainless steel (Inox) channels: Deployed manually or via motorization for high-throughput environments, guiding parts without exposure to the ring.

Discussion

The Ring of Concern, while theoretically susceptible to contamination, is effectively controlled through a multi-tiered approach. Empirical data and routine use indicate that contamination incidents are infrequent and almost always attributable to human error rather than design failure. The combination of validated disinfection protocols and mechanical isolation mechanisms render the Rapid Transfer Port interface safe for daily use, even in critical applications.

Pressure differential studies reinforce this view. In one experiment, an Rapid Transfer Port was exposed to a heavily contaminated environment (10⁶ cfu/m³ of *Bacillus subtilis thermophilus*) under positive pressure. The contaminated chamber was maintained at +120 Pa while the Grade A isolator remained at +20 Pa. Despite visible spores on seals, no ingress was observed into the sterile zone after multiple transfers, underscoring the containment integrity of the system.

The 2022 revision of EU GMP Annex 1 further highlights the importance of science- and risk-based contamination control strategies. Rapid Transfer Ports, including their potential weaknesses like the Ring of Concern, should be evaluated based on real-life data rather than theoretical risks alone. The prevalence of over 40,000 alpha ports in daily pharmaceutical use, performing hundreds of thousands of transfers, supports their proven reliability.

Conclusion

While the Ring of Concern represents a minor theoretical risk within Rapid Transfer Port systems, its significance in practice is minimal when appropriate controls are in place. Extensive field testing, surface decontamination protocols, and innovative engineering solutions ensure the integrity of aseptic transfers across pharmaceutical production lines.

Rapid Transfer Port technology remains a cornerstone of pharmaceutical manufacturing, especially for high-potency or sterile applications. The industry’s continued vigilance through routine monitoring, validation of disinfectant efficacy, and adherence to evolving regulatory expectations ensures that the risks associated with Rapid Transfer Port interfaces remain tightly controlled.

Ongoing studies, increased data transparency, and broader application of advanced engineering features will continue to strengthen the foundation of aseptic transfer technologies well into the future.

Rapid Transfer Ports in Aseptic and Contained Pharmaceutical Manufacturing: Principles, Use, and Technological Advances

---

Rapid Transfer Ports (RTPs) are a cornerstore technology in maintaining sterile or high-containment conditions during material transfers in pharmaceutical manufacturing. This paper provides a comprehensive overview of RTP functionality, technical components, operation protocols, contamination control strategies, and integration into barrier systems including isolators and RABS.

1. Introduction

The increasing complexity of pharmaceutical manufacturing – particularly in aseptic processing and highly potent active pharmaceutical ingredient (HPAPI) handling – demands robust technologies  for maintaining environmental integrity. Rapid Transfer Ports (RTPs) address this need by providing a validated, closed-system method for transferring materials in and out of sterile or contained spaces without compromising product or operator safety.

2. Functional Overview of Rapid Transfer Ports

RTPs are mechanical devices enabling the connection between two segregated environments – typically between a Grade A isolator interior and the external cleanroom or a process interface. The RTP system is composed of:

• Alpha Port: A fixed unit integrated into a barrier wall (e.g., isolator or RABS), with a sealed door.
• Beta Part: A mobile container, flange, or bag with a corresponding door and locking interface.

Upon secure docking and alignment, the double-door system allows for simultaneous opening of both doors, creating a shared sterile/contained space for material transfer.

3. Operational Procedure

The standardized operational sequence for RTP use is as follows:

1. Alignment: The beta flange or container is aligned with the Alpha Port using integrated mechanical guides.
2. Locking: A bayonet or cam-lock machanism secures the connection to ensure leak-tight integrity.
3. Rotational Activation: The beta unit is rotated (typically 60° to 120°), simultaneously opening both doors.
4. Tranfer: Materials are transferred without breach of sterility or containment.
5. Disengagement: The beta unit is counter-rotated to close the doors, then unlocked and removed.

4. Contamination Control and System Integrity

RTPs serve as a critical control point in contamination prevention and environmental isolation. Their core integrity relies on:

• Double-door sealed interfaces
• Elastomeric gaskets
• Pressure and integrity validation
• Microbiological qualification using surrogate models

Systems are validated according to ISO 14644-7 Annex 1 and aligned with cGMP regulations.

5. Ergonomics and Usability

Despite their technical complexity, RTPs are designed for operational efficiency. Key features include:

• Single-hand ergonomic operation
• Visual and audible feedback
• Beta containers in lightweight materials
• Modular compatibility with single-use, reusable, and robotic  systems

Training and SOP standardization are essential for operational consistency.

6. Safety and Regulatory Compliance

RTPs must safeguard both product sterility and operator exposure. Safety features include:

• Containment capabilities up to OEB 6
• Compliance with FDA 21 CFR Part 11
• Validated cleaning protocols

Routine validation includes visual inspections, integrity testing, and cycle counting.

7. Validation of Rapid Transfer Ports

Validation of RTPs is critical to ensure their effectiveness in maintaining sterility and containment during material transfers in pharmaceutical manufacturing. Key validation parameters include airflow dynamics, leak integrity, decontamincation efficacy, and containment performance.

7.1 Airflow Dynamics and Particle Control

Studies show that airflow velocity and distribution significantly impact particle removal efficiency. Uniform airflow is essential for maintaining ISO Class 5 conditions within RTP chambers.

7.2 Leak integrity Testing

Leak testing, typically via pressure decay methods, ensures airtight integrity. These tests reliably detect potential breaches that could compromise containment.

7.3 Decontamination Efficacy

Decontamination using vaporized hydrogen peroxide (VHP) is validated to ensure sterilization of all internal surfaces, provided sufficient VHP concentration and exposure time.

7.4 Containment performance

Containment validation confirms the system’s ability to manage potent substances without environmental release, demonstrating performance up to OEB 6 in appropriate configurations.

8. Applications and Use Cases

RTPs are used accross various sterile and containment applications, such as:

• Aseptic fill-finish lines
• Sterility test isolators
• HPAPI compounding
• Microbiological quality control laboratories
• Cell and gene therapy manufacturing environments

9. Industry Guidelines and Best Practices

9.1 PDA Recommendations

The Parenteral Drug Association emphasizes that sterile material transfer remains a key in contamination risk. They recommend robust contamination control strategies aligned with EU GMP Annex 1 and WHO GMP.

9.2 ISPE Guidelines

The International Society for Pharmaceutical Engineering provides guidance on containment equipment selection and performance. Their Good Practice Guides highlight RTPs’ roles in RABS and other barrier systems, noting their contribution to operator segregation and aseptic integrity.

Rapid Transfer Ports are an indispensable element in modern pharmaceutical manufacturing, enabling safe, sterile, and efficient transfer of materials. With increasing demand for sterility and containment assurance, RTP technology continues to evolve, offering enhanced safety, modularity, and process integration.

ABC Transfer® Alpha Port

ABC Transfer, leader in sterile transfer systems, appoints RAVONA as exclusive distributor in Israel

ABC Transfer, a global leader in the design and manufacturing of state-of-the-art sterile transfer systems, has announced the appointment of RAVONA as its exclusive distributor in Israel. This strategic partnership aims to strengthen ABC Transfer’s presence in the Israeli market while providing the local Pharmaceutical Industry with access to cutting-edge solutions for aseptic transfer.

Pioneering sterile transfer systems.

ABC Transfer has built a reputation as an innovator in sterile transfer systems, setting new standards in pharmaceutical, biotech, and healthcare applications. Our solutions are recognized for enabling contamination-free transfers of materials between controlled environments, a critical need in indutries with stringent sterility requirements.

The company’s portfolio includes cutting-edge equipment such as Rapid Transfer Ports (RTPs) and Betacleanbags, which ensure the integrity of aseptic environments during material transfer, and advanced technologies designed to meet the evolving demands of modern Pharmaceuticals manufacturing. These systems are widely adopted by pharmaceutical and biopharma companies, research labs, and other high-containment facilities globally.

By appointing RAVONA, ABC Transfer is now positioned to deliver these advanced solutions to Israeli stakeholders, fostering enhanced safety and efficiency in the country’s thriving life sciences sector.

RAVONA: A trusted name in Israel’s industrial landscape

Established in 1962, RAVONA has grown to become a prominent supplier of high-tech solutions across a range of industries in Israel, including pharmaceuticals, food production, and electronics. The company is celebrated for its technical expertise, robust distribution network, and unwavering commitment to customer satisfaction.

RAVONA’s partnership with global technology leaders has made it a reliable source for high-quality equipment and services tailored to meet the unique needs of Israeli enterprises. With a skilled team of engineers and a history of successful collaborations, RAVONA is ideally positioned to represent ABC Transfer’s cutting-edge sterile transfer systems.

Meeting the growing demand for aseptic solutions

The Israeli life sciences market is expanding rapidly, fueled by investments in research and development, innovative biotech startups, and a strong regulatory framework. As the demand for advanced sterile manufacturing and containment technologies grows, the partnership between ABC Transfer and RAVONA will play a pivotal role in equipping Israeli manufacturers with the tools necessary to maintain global compliance and ensure product safety.

ABC Transfer’s sterile transfer systems, which are recognized for their durability, precision, and compliance with international standards such as ISO 14644 and cGMP, will now be readily available to Israeli customers. RAVONA’s local expertise will also ensure that clients receive tailored solutions and seamless technical support, from installation to maintenance.

A vision for the future

Speaking about the partnership, ABC Transfer CEO, Thierry Girard expressed confidence in RAVONA’s ability to drive adoption of their sterile transfer systems in Israel. “We are delighted to collaborate with RAVONA, a company that shares our values of innovation, quality, and customer focus. Together, we aim to empower Israeli industries with state-of-the-art solutions that redefine sterile transfer processes,” they stated.

Meanwhile, Amit RAVONA, Head of Business Development said: “We welcome the opportunity to represent such a prestigious global leader. ABC Transfer’s products are an excellent addition to our portfolio. We are proud to bring their groundbreaking technologies to Israel and look forward to supporting the pharmaceutical and biotech sectors in achieving the highest standards of sterility.”

ABC Transfer appoints JMC Project Services as its exclusive agent in Ireland

JMC Project Services Limited is a wholly owned Irish company established with a view to offering a one stop shop for companies purchasing equipment and services in the Lifesciences Industries. The Company represents a number of local and international companies who specialise in the supply of a range of equipment designed specifically for use in GMP regulated industries. JMC Project Services Vison is to provide the Pharmaceutical, Biopharmaceutical, Food and Energy industries in Ireland with the most efficient and innovative solutions for process and facility implementation and optimization.

JMC Project Services is managed by John McHugh, an experienced business development Manager, and Paul Cuddy, an accomplished Sales Manager with a demonstrated history of working in the Pharmaceutical and Medical Devices Industries.

The Pharmaceutical industry in Ireland

Ireland has one of the largest pharmaceutical Industry. More than 90 pharmaceutical companies operate in Ireland including ten of the top 10 Bio-Pharma companies. Fifty manufacturing plants are FDA-approved. Ireland is the third largest global exporter of pharmaceutical products with €116bn of sales revenue. More than 90,000 employees work in that Industry. Several very large investments have recently been announced. Pfizer for example has announced close to €2bn of investment in several projects. BMS have announced €400M of CAPEX for capacity improvements and Astellas more than €300M for a new facility. This makes Ireland one of the most dynamic countries in Global Pharma.

ABC Transfer®, an expert in Rapid Transfer Ports (RTP)

ABC Transfer® was founded in 2019 by two experts in the Pharmaceutical Industry, to introduce disruptive innovations in the Global RTP (Rapid Transfer Ports) market. Working very closely with several of the top ten brands, ABC Transfer® has identified and solved more than 70 pain points the industry has been experiencing for decades. The Company has anticipated the introduction of the annex1 of the European GMPs and has designed simple and reliable solutions to comply with this new regulation as well as the introduction of robotics and cobotics in the Pharmaceutical Industry. With the recent introduction, at ACHEMA 2024, of its revolutionary ULTRA system, ABC Transfer® expert in RTP solutions (rapid transfer ports) has become the only Brand to propose a fully integrated gloveless system for single use transfer applications. ABC Transfer® ULTRA is the first aseptic transfer system specifically designed for the sterile transfer of components via ported bags, without the need for glove ports. Several Customers have already standardized their production lines with ULTRA. ABC Transfer® has been committed since its creation, to adopting a responsible and sustainable business model in the fight against global warming. The company claims a zero net carbon footprint by designing products, which are fully recyclable, by using 50% less plastics than existing solutions, and by compensating 100% of its remaining CO2 emissions.

ABC Transfer® ULTRA

Introduction of ABC Transfer’s rapid transfer systems in Ireland

JMC Project Services will help introduce ABC Transfer’s innovative and Annex 1-compliant RTP solutions in the Irish market and develop the product range further in compliance with the specific requirements of the Irish market.

ABC Transfer’s CEO Thierry Girard says “we look forward to an exciting future with JMC Project Services in one of the largest and most advanced global Bio-Pharma market. We’ll be attending several conferences in the Fall together and we look forward to discussing with Irish Customers”.

The main contacts are Paul Cuddy, Sales Director and John McHugh, Managing Director.

You may find additional information on JMC Project Services at www.jmcpsl.com.